导师风采
王燕
个人信息
Personal Information
- 性别：女
- 导师类型：博士生导师
- 职称：主任医师
- 该职称任职时间：20110701
联系方式
Contact Information
- 所属院系：肿瘤医院
- 所属专业：
- 邮箱 : wangyanyifu@163.com
- 工作电话 : 87788519
个人简介
Personal Profile
一直从事肿瘤内科临床、教学与研究工作，曾在英国和美国进修，主要擅长肺癌、胸腺瘤、间皮瘤等胸部恶性肿瘤的规范化和个体化治疗，尤其对肺癌精准靶向个体化治疗有丰富经验和深厚造诣，对靶向治疗耐药及少见突变有深入研究，熟悉多种肿瘤的免疫治疗。此外对其他常见恶性肿瘤的化疗和靶向治疗也有较丰富的经验。主要负责并参与完成了六十余项国际和国内的靶向药物及免疫治疗药物的临床研究，主持国自然1项，承担多个部级和院校级课题，参与《临床肿瘤内科手册》、《抗肿瘤药物手册》等8部肿瘤学经典专著的编写。担任多个肺癌相关专业杂志的编委，发表学术论文60余篇，每年都带领学生把研究成果在发布在ASCO，WCLC等国际会议及国内重要肺癌领域会议上。
团队简介
Team Profile
待补充更新
- 研究方向Research Directions
肿瘤内科治疗,肺癌分子靶向及免疫治疗,耐药机制转化研究
- 在校研究生Current Graduate Students
硕士研究生 0 名，博士研究生 5 名
- 科研项目Research Projects
| # | 项目名称 | 起止日期 | 金额 | 项目类型 | 本人角色 |
|---|---|---|---|---|---|
| 1 | 西达本胺联合信迪利单抗治疗晚期耐药性NSCLC的前瞻性、多队列Ib/II期临床研究 | 2020-09-01 —— | 5.0 | 主持者 | |
| 2 | KRAS突变调控TRIM9差异表达在非小细胞肺癌抗PD-1免疫治疗原发耐药中的机制研究 | 2021-01-01 —— | 55.0 | 主持在研的国家或省部级科研项目 | 主持者 |
| 3 | 非小细胞肺癌术后脑转移与术中区域淋巴结转移的生物学相关性探索研究 | 2022-06-01 —— | 5.0 | 主持者 | |
| 4 | RANKL/RANK 通路调控KRAS 突变非小细胞肺癌抗 PD-1 免疫治疗耐药的转化研究 | 2022-10-01 —— | 50.0 | 主持者 | |
| 5 | 探索特瑞普利单抗联合安罗替尼二线/三线治疗EGFR突变耐药的晚期非鳞非小细胞肺癌的II期临床研究 | 2019-10-01 —— | 38.8 | 主持者 |
- 发表论文Papers
| # | 论文题目 | 期刊名称 | 发表年份 | 论文署名 |
|---|---|---|---|---|
| 1 | Treatment outcome and clinical characteristics of HER2 mutated advanced non-small cell lung cancer patients in China. | Thorac Cancer | 2022-06-13 | 王燕 |
| 2 | 肺癌免疫治疗耐药机制及应对策略 | 中国肺癌杂志 | 2022-06-13 | 王燕 |
| 3 | 程序性死亡受体-1及程序性死亡受体-配体1抑制剂在小细胞肺癌治疗中的进展 | 中华肿瘤杂志 | 2022-06-13 | 王燕 |
| 4 | 表皮生长因子受体基因20号外显子插入突变型非小细胞肺癌的治疗现状与展望 | 中华肿瘤杂志 | 2022-06-13 | 王燕 |
| 5 | Superior efficacy of immunotherapy-based combinations over monotherapy for EGFR-mutant non-small cell lung cancer acquired resistance to EGFR-TKIs. | Thorac Cancer | 2022-06-13 | 王燕 |
| 6 | The commensal consortium of the gut microbiome is associated with favorable responses to anti-programmed death protein 1 (PD-1) therapy in thoracic neoplasms. | Cancer Biol Med. | 2022-06-13 | 王燕 |
| 7 | Apatinib in combination with pemetrexed-platinum chemotherapy for chemo-naive non-squamous non-small cell lung cancer: a phase II clinical study. | Lung Cancer | 2022-06-13 | 王燕 |
| 8 | First-line immunotherapy or angiogenesis inhibitor plus chemotherapy for HER2-altered NSCLC: a retrospective real-world POLISH study. | Ther Adv Med Oncol | 2022-06-19 | 王燕 |
| 9 | 多项肺系统肿瘤标志物异常在晚期肺腺癌治疗中的作用 | 中国肺癌杂志 | 2022-06-13 | 王燕 |
| 10 | The value of blood biomarkers of progression and prognosis in ALK-positive patients with non-small cell lung cancer treated with crizotinib | Asia Pac J Clin Oncol. | 2022-06-13 | 王燕 |
| 11 | Comparing first-line treatment patterns and clinical outcomes of patients with pan-negative advanced non-squamous non-small cell lung cancer. | Thorac Cancer | 2022-06-13 | 王燕 |
| 12 | 实体瘤患者发生血流感染的病原学特点及预后分期 | 中华医院感染学杂志 | 2022-06-13 | 王燕 |
| 13 | 阿帕替尼治疗晚期非小细胞肺癌的研究进展 | 癌症进展 | 2022-06-13 | 王燕 |
| 14 | Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer Patients. | Clin Cancer Res | 2022-06-13 | 王燕 |
| 15 | EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study. | Lung cancer | 2022-06-13 | 王燕 |
| 16 | The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity. | Cancer Letters. | 2022-06-13 | 王燕 |
| 17 | 晚期野生型非小细胞肺癌内科治疗热点及展望 | 癌症进展 | 2022-06-13 | 王燕 |
| 18 | 人表皮生长因子受体2突变型非小细胞肺癌的治疗现状与展望 | 中华肿瘤杂志 | 2022-06-13 | 王燕 |
| 19 | Tumor Differentiation and EGFR Mutation Associated with Disease-Free Survival in Stage IA Lung Adenocarcinoma Patients with Curative Surgery. | Cancer Management and Research | 2022-06-13 | 王燕 |
| 20 | EGFR基因阳性晚期非小细胞肺癌患者的免疫治疗策略 | 癌症进展 | 2022-06-13 | 王燕 |
| 21 | 非小细胞肺癌少见基因突变的治疗研究进展 | 癌症进展 | 2022-06-13 | 王燕 |
| 22 | Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis. | J Immunother Cancer | 2022-06-13 | 王燕 |
| 23 | Favorable predictors for survival in advanced ALK-positive non-small cell lung cancer patients beyond crizotinib resistance. | Thorac Cancer | 2022-06-13 | 王燕 |
| 24 | 新型冠状病毒肺炎疫情期间肺癌患者的内科诊疗策略 | 中华肿瘤杂志 | 2022-06-13 | 王燕 |
| 25 | 优化解决肺癌患者在新型冠状病毒肺炎疫情期间诊疗问题及心理问题的探索 | 中国肺癌杂志 | 2022-06-13 | 王燕 |
| 26 | Crizotinib vs platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer with different ROS1 fusion variants. | Cancer Med | 2022-06-13 | 王燕 |
| 27 | Heterogeneous Response to First-Generation Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancers with Different EGFR Exon 19 Mutations | Target Oncol | 2022-06-13 | 王燕 |
| 28 | Osimertinib for the treatment of epidermal growth factor receptor–mutated non-small cell lung cancer patients with leptomeningeal metastases and different T790M status. | Ann Transl Med | 2022-06-13 | 王燕 |
| 29 | 小细胞肺癌免疫治疗疗效预测指标的现状与未来 | 中国肺癌杂志 | 2022-06-13 | 王燕 |
| 30 | Sequential therapy according to distinct disease progression patterns in advanced ALK-positive non-small-cell lung cancer after crizotinib treatment. | Chin J Cancer Res | 2022-06-13 | 王燕 |
| 31 | Remarkable response of BRAF V600E-mutated metastatic pancreatic cancer to BRAF/MEK inhibition: a case report. | Gastroenterol Rep (Oxf) | 2022-06-19 | 王燕 |
| 32 | A Linear Discriminant Analysis Model Based on the Changes of 7 Proteins in Plasma Predicts Response to Anlotinib Therapy in Advanced Non-Small Cell Lung Cancer Patients. | Front Oncol | 2022-06-19 | 王燕 |
| 33 | Limited role of KRAS mutation in guiding immunotherapy in advanced non-small-cell lung cancer. | Future Oncol | 2022-06-19 | 王燕 |
| 34 | Systematic analysis of IL-6 as a predictive biomarker and desensitizer of immunotherapy responses in patients with non-small cell lung cancer. | BMC Medicine | 2022-06-19 | 王燕 |
| 35 | The Lifted Veil of Uncommon EGFR Mutation p.L747P in Non-Small Cell Lung Cancer: Molecular Feature and Targeting Sensitivity to Tyrosine Kinase Inhibitors. | Front Oncol | 2022-06-19 | 王燕 |
| 36 | Novel genetic characteristics in low-grade fetal adenocarcinoma of the lung. | Thorac cancer | 2022-06-19 | 王燕 |
| 37 | Afatinib and Dacomitinib Efficacy, Safety, Progression Patterns, and Resistance Mechanisms in Patients withNon‐Small Cell Lung Cancer Carrying Uncommon EGFR Mutations:A Comparative Cohort Study in China (AFANDA Study) | Cancers | 2023-07-02 | 王燕 |
| 38 | EGFR uncommon alterations in advanced non-small cell lung cancer and structural insights into sensitivity to diverse tyrosine kinase inhibitors | Frontiers in Pharmacology | 2023-07-02 | 王燕 |
| 39 | Adjuvant chemotherapy in patients with recurrence after completely resected stage IB lung adenocarcinoma: Propensity-matched analysis in a cohort of 147 recurrences | Thoracic Cancer | 2023-07-02 | 王燕 |
| 40 | Organ--specific immune checkpoint inhibitor treatment in lung cancer: a systematic review and meta--analysis | BMJ Open | 2023-07-02 | 王燕 |
| 41 | Pyrotinib combined with apatinib for targeting metastatic non-small cell lung cancer with HER2 alterations: a prospective, open-label, single-arm phase 2 study (PATHER2) | BMC Medicine | 2023-07-02 | 王燕 |
| 42 | Efficacy and safety of concomitant immunotherapy and denosumab in patients with advanced non-small cell lung cancer carrying bone metastases: A retrospective chart review | Frontiers in Immunology | 2023-07-02 | 王燕 |
| 43 | Dacomitinib for Advanced Non-small Cell Lung Cancer Patients Harboring Major Uncommon EGFR Alterations: A Dual-Center, Single-Arm, Ambispective Cohort Study in China | Frontiers in Pharmacology | 2023-07-02 | 王燕 |
| 44 | 循环肿瘤DNA在非小细胞肺癌诊疗中的研究进展 | 中国肺癌杂志 | 2023-07-02 | 王燕 |
| 45 | Heterogeneity in intracranial relapses after complete resection of lung adenocarcinoma: Distinct features of brain-only relapse versus synchronous extracranial relapse | Cancer Medicine | 2023-07-02 | 王燕 |
| 46 | RANKL acts an unfavorable prognostic biomarker and potential target in advanced KRAS-mutated lung adenocarcinoma | Thoracic Cancer | 2023-07-02 | 王燕 |
| 47 | Targeting exon 20 insertion mutations in lung cancer. | CURRENT OPINION IN ONCOLOGY | 2023-07-02 | 王燕 |
| 48 | An exploration of LAF-bTMB as a predictor for the efficacy of immunotherapy combined with chemotherapy in non—small cell lung cancer | Thoracic Cancer | 2023-07-02 | 王燕 |
| 49 | Treatment patterns and outcomes of immunotherapy in extensive-stage small-cell lung cancer based on real-world practice | Thoracic Cancer | 2023-07-02 | 王燕 |
| 50 | EGFR exon 20 insertion variants A763_Y764insFQEA and D770delinsGY confer favorable sensitivity to currently approved EGFR-specific tyrosine kinase inhibitors. | Frontiers in Pharmacology | 2023-07-02 | 王燕 |
| 51 | Possibility of brigatinib-based therapy, or chemotherapy plus anti-angiogenic treatment after resistance of osimertinib harboring EGFR T790M-cis-C797S mutations in lung adenocarcinoma patients. | Cancer Med | 2022-06-19 | 王燕 |
| 52 | EGFR Exon 18 Mutations in Advanced Non-Small Cell Lung Cancer: A Real-World Study on Diverse Treatment Patterns and Clinical Outcomes. | Front Oncol | 2022-06-19 | 王燕 |
| 53 | First-line immunotherapy or angiogenesis inhibitor combined with chemotherapy for advanced non-small cell lung cancer with EGFR exon 20 insertions: Real-world evidence from China. | Cancer Med | 2022-06-19 | 王燕 |
| 54 | Specific HER2 Exon 20 Gly776 Deletion-Insertions in Non-Small Cell Lung Cancer: Structural Analysis and Sensitivity to HER2-Targeted Tyrosine Kinase Inhibitors. | Front Pharmacology | 2022-06-19 | 王燕 |
| 55 | Efficacy of dacomitinib in patients with non-small cell lung cancer carrying complex EGFR mutations: a real-world study. | J Thorac Dis | 2022-06-19 | 王燕 |
| 56 | A real-world study of dacomitinib in later-line settings for advanced non-small cell lung cancer patients harboring EGFR mutations. | Cancer Med | 2022-06-19 | 王燕 |
| 57 | I期非小细胞肺癌预后因素和术后辅助治疗进展 | 癌症进展 | 2022-06-13 | 王燕 |
| 58 | Clinical characteristics and response to tyrosine kinase inhibitors of patients with non-small cell lung cancer harboring uncommon epidermal growth factor receptor mutations | Chin J Cancer Res | 2022-06-13 | 王燕 |
| 59 | Genomic profile and immune microenvironment in patients with relapsed stage IA lung adenocarcinoma. | Translational Oncology | 2022-06-13 | 王燕 |
| 60 | The prognostic value of a Methylome-based Malignancy Density Scoring System to predict recurrence risk in early-stage Lung Adenocarcinoma | Theranostics | 2022-06-13 | 王燕 |
| 61 | Case Report: Dacomitinib May Not Benefit Patients Who Develop Rare Compound Mutations After Later-Line Osimertinib Treatment. | Fron Oncol | 2022-06-13 | 王燕 |
| 62 | Treatment duration as a surrogate endpoint to evaluate the efficacy of crizotinib in sequential therapy for patients with advanced ALK-positive non-small cell lung cancer: A retrospective, real-world study. | Cancer Med | 2022-06-13 | 王燕 |
| 63 | Combination TS-1 plus EGFR-tyrosine kinase inhibitors (TKIs) for the treatment of non-small cell lung cancer after progression on first-line or further EGFR-TKIs: A phase II, single-arm trial. | Thorac Cancer | 2022-06-13 | 王燕 |
| 64 | Osimertinib for Chinese advanced non-small cell lung cancer patients harboring diverse EGFR exon 20 insertion mutations | Lung Cancer | 2022-06-13 | 王燕 |
- 科研获奖Research Awards
| # | 获奖证书编号 | 奖项名称 | 获奖级别 | 获奖类别 | 获奖等级 | 获奖日期 | 颁奖单位 | 本单位是否为第一完成单位 | 完成单位排名 | 本人排序 | 备注 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2022医-2-110-04 | 北京市科学技术奖 | 省部级 | 省（市、自治区）政府自然科学奖、技术发明奖 | 二等奖 | 2023-06-12 | 北京市人民政府 | 是 | 1 | 4 |
- 研究成果Research Findings
| # | 成果类型 | 项目/专利/新品种名称 |
|---|---|---|
| 1 | 作为主创人员获得授权的发明专利和新品种 | IL-6在非小细胞肺癌免疫治疗中的应用 |
| 2 | 出版高水平专著 | 《肺癌诊断治疗学》 |
| 3 | 出版高水平专著 | 《常见恶性肿瘤治疗手册》 |
| 4 | 出版高水平专著 | 《常用抗肿瘤药物手册》 |
| 5 | 出版高水平专著 | 《临床肿瘤内科手册（第五版）》 |